Crossover Study to Assess the Safety and Pharmacokinetic of Pegylated Somatropin(PEG Somatropin) in GHD Children

A Phase 1, Open-Label, Single and Multiple Dose Study to Assess the Safety and Pharmacokinetics of Pegylated Somatropin(PEG Somatropin) in GHD Children

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01613573

Acronym

Phase 1

Enrollment

Registered

2012-06-07

Start date

2010-03-31

Completion date

2010-11-30

Last updated

2012-06-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Growth Hormone Deficiency

Keywords

pegylated Somatropin, PEG-GH, Phase 1 study, Pharmacokinetics

Brief summary

The purpose of the phase 1 study is to assess the safety and pharmacokinetics of PEG somatropin, which administered once per week, compared with the daily used somatropin, and to evaluate the safety and possibility to replace daily used somatropin.

Interventions

DRUGsomatropin AQ

somatropin injection 0.2mg/kg/w once per day, inject for 7 continuous days 4 weeks for cleaning period

DRUGpegylated somatropin

Pegylated somatropin 0.2mg/kg/w once per week, for continuous 6 weeks Subcutaneous injection

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

MALE

Age

4 Years to 10 Years

Healthy volunteers

Inclusion criteria

* have a height less than two standard deviations (SD) below the median height for individuals of the same age or height, a growth velocity (GV) ≤4 cm/yr, a GH peak concentration \<7 ng/ml in two different provocative tests, a bone age (BA; ≤9 years in girls and ≤10 years in boys) at least 2 years less than his/her chronological age (CA);be in preadolescence (Tanner stage 1) and have a CA \>3 years;have a height value recorded 3 months before the start of GH treatment to calculate pre-treatment GV; receive no prior GH treatment or stop the GH treatment for more than 4 weeks;sign informed consent

Exclusion criteria

* Patients with Liver and kidney dysfunction (ALT\> upper limit of normal 2 times, Cr\> upper limit of normal), hepatitis B virus detection, antigen-HBc, HBsAg and HBeAg are positive * patients with known to a highly allergic constitution or allergic to the drug of this study * Patients with diabetes, serious cardiopulmonary, blood system, malignant tumor and other diseases or systemic infection in immunocompromised and mental diseases * Patients with other growth disorders, such as Turner syndrome, constitutional delay of growth and puberty, Laron syndrome, GH receptor deficiency, girls with growth delay have not ruled out chromosomal abnormalities * Participated in clinical trials of other drugs in 3 months * Other cases that the researchers considered unsuitable for this clinical trial

Design outcomes

Primary

Measure	Time frame	Description
pharmacokinetics parameter	Somatropin AQ: predose(0),1,2,3,4,6,8,10,12,16,20,24 hours post-dose. PEG somatropin: predose (0),2,4,8,12,18,24,36,48,72,96,120,144,168 hours post-dose	Cmax, AUC during the time interval for the first dose and last dose, Half-Life(t1/2), Apparent body clearance(CL), Mean residence time(MRT),steady-state volume of distribution(Vss)

Secondary

Measure	Time frame
IGF-1, IGFBP-3	Day I to Day 7 in each treatment period (33 time points) for daily used somatropin, Day I to Day 42 in each treatment period (35 time points) for PEG somatropin

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026